474 related articles for article (PubMed ID: 32217187)
1. The journey to a respiratory syncytial virus vaccine.
Mejias A; Rodríguez-Fernández R; Oliva S; Peeples ME; Ramilo O
Ann Allergy Asthma Immunol; 2020 Jul; 125(1):36-46. PubMed ID: 32217187
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus vaccine: where are we now and what comes next?
Noor A; Krilov LR
Expert Opin Biol Ther; 2018 Dec; 18(12):1247-1256. PubMed ID: 30426788
[TBL] [Abstract][Full Text] [Related]
3. Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants.
Browne SK; Beeler JA; Roberts JN
Vaccine; 2020 Jan; 38(2):101-106. PubMed ID: 31706809
[TBL] [Abstract][Full Text] [Related]
4. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
5. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
Rossey I; Saelens X
Expert Rev Vaccines; 2019 Oct; 18(10):1053-1067. PubMed ID: 31587585
[No Abstract] [Full Text] [Related]
6. Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods.
Smith TRF; Schultheis K; Broderick KE
Hum Vaccin Immunother; 2017 Nov; 13(11):2626-2629. PubMed ID: 28881156
[TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.
Esposito S; Di Pietro G
Future Microbiol; 2016 Oct; 11():1479-1490. PubMed ID: 27750448
[TBL] [Abstract][Full Text] [Related]
8. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
[TBL] [Abstract][Full Text] [Related]
9. Current progress on development of respiratory syncytial virus vaccine.
Chang J
BMB Rep; 2011 Apr; 44(4):232-7. PubMed ID: 21524347
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus vaccine development.
Murata Y
Clin Lab Med; 2009 Dec; 29(4):725-39. PubMed ID: 19892231
[TBL] [Abstract][Full Text] [Related]
11. Advances in and the potential of vaccines for respiratory syncytial virus.
Jorquera PA; Oakley KE; Tripp RA
Expert Rev Respir Med; 2013 Aug; 7(4):411-27. PubMed ID: 23964629
[TBL] [Abstract][Full Text] [Related]
12. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
Wright PF; Karron RA; Belshe RB; Shi JR; Randolph VB; Collins PL; O'Shea AF; Gruber WC; Murphy BR
Vaccine; 2007 Oct; 25(42):7372-8. PubMed ID: 17868959
[TBL] [Abstract][Full Text] [Related]
13. Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development.
Boyoglu-Barnum S; Chirkova T; Anderson LJ
Front Immunol; 2019; 10():1675. PubMed ID: 31402910
[TBL] [Abstract][Full Text] [Related]
14. Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease.
Kotomina T; Isakova-Sivak I; Matyushenko V; Kim KH; Lee Y; Jung YJ; Kang SM; Rudenko L
Antiviral Res; 2019 Aug; 168():9-17. PubMed ID: 31075351
[TBL] [Abstract][Full Text] [Related]
15. Advances in RSV vaccine research and development - A global agenda.
Higgins D; Trujillo C; Keech C
Vaccine; 2016 Jun; 34(26):2870-2875. PubMed ID: 27105562
[TBL] [Abstract][Full Text] [Related]
16. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
[TBL] [Abstract][Full Text] [Related]
17. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein.
Xue M; Wang R; Harder O; Chen P; Lu M; Cai H; Li A; Liang X; Jennings R; La Perle K; Niewiesk S; Peeples ME; Li J
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999025
[TBL] [Abstract][Full Text] [Related]
18. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
Munoz FM
Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
[TBL] [Abstract][Full Text] [Related]
20. Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop.
Roberts JN; Graham BS; Karron RA; Munoz FM; Falsey AR; Anderson LJ; Marshall V; Kim S; Beeler JA
Vaccine; 2016 Sep; 34(41):4843-4849. PubMed ID: 27566900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
